266 related articles for article (PubMed ID: 31391192)
1. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Yang H; Shu Z; Jiang Y; Mao W; Pang L; Redwood A; Jeter-Jones SL; Jennings NB; Ornelas A; Zhou J; Rodriguez-Aguayo C; Bartholomeusz G; Iles LR; Zacharias NM; Millward SW; Lopez-Berestein G; Le XF; Ahmed AA; Piwnica-Worms H; Sood AK; Bast RC; Lu Z
Clin Cancer Res; 2019 Sep; 25(18):5702-5716. PubMed ID: 31391192
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
[No Abstract] [Full Text] [Related]
3. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.
Ros S; Flöter J; Kaymak I; Da Costa C; Houddane A; Dubuis S; Griffiths B; Mitter R; Walz S; Blake S; Behrens A; Brindle KM; Zamboni N; Rider MH; Schulze A
Oncogene; 2017 Jun; 36(23):3287-3299. PubMed ID: 28092678
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
[TBL] [Abstract][Full Text] [Related]
5. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
Zhang S; Lu Z; Mao W; Ahmed AA; Yang H; Zhou J; Jennings N; Rodriguez-Aguayo C; Lopez-Berestein G; Miranda R; Qiao W; Baladandayuthapani V; Li Z; Sood AK; Liu J; Le XF; Bast RC
PLoS One; 2015; 10(7):e0131833. PubMed ID: 26146988
[TBL] [Abstract][Full Text] [Related]
6. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S; Zhao M; Yuca E; Annis A; Evans K; Sutton D; Carvajal L; Ren JG; Santiago S; Guerlavais V; Akcakanat A; Tapia C; Yang F; Bose PSC; Zheng X; Dumbrava EI; Aivado M; Meric-Bernstam F
Breast Cancer Res; 2021 Mar; 23(1):29. PubMed ID: 33663585
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of A-kinase anchor protein 4 inhibits proliferation of triple-negative breast cancer cells
Jagadish N; Devi S; Gupta N; Suri V; Suri A
Tumour Biol; 2020 Apr; 42(4):1010428320914477. PubMed ID: 32342732
[TBL] [Abstract][Full Text] [Related]
9. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
10. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
[TBL] [Abstract][Full Text] [Related]
11. TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Ko YH; Domingo-Vidal M; Roche M; Lin Z; Whitaker-Menezes D; Seifert E; Capparelli C; Tuluc M; Birbe RC; Tassone P; Curry JM; Navarro-Sabaté À; Manzano A; Bartrons R; Caro J; Martinez-Outschoorn U
J Biol Chem; 2016 Dec; 291(51):26291-26303. PubMed ID: 27803158
[TBL] [Abstract][Full Text] [Related]
12. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
13. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
14. PFKFB2 is a favorable prognostic biomarker for colorectal cancer by suppressing metastasis and tumor glycolysis.
Liu F; Wei X; Chen Z; Chen Y; Hu P; Jin Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10737-10752. PubMed ID: 37311985
[TBL] [Abstract][Full Text] [Related]
15. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Xiang F; Ni Z; Zhan Y; Kong Q; Xu J; Jiang J; Wu R; Kang X
Tumour Biol; 2016 May; 37(5):6017-25. PubMed ID: 26596839
[TBL] [Abstract][Full Text] [Related]
17. Akt-dependent activation of the heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB2) isoenzyme by amino acids.
Novellasdemunt L; Tato I; Navarro-Sabate A; Ruiz-Meana M; Méndez-Lucas A; Perales JC; Garcia-Dorado D; Ventura F; Bartrons R; Rosa JL
J Biol Chem; 2013 Apr; 288(15):10640-51. PubMed ID: 23457334
[TBL] [Abstract][Full Text] [Related]
18. Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells.
Lim SJ; Choi HG; Jeon CK; Kim SH
Oncol Rep; 2015 Apr; 33(4):2023-30. PubMed ID: 25647149
[TBL] [Abstract][Full Text] [Related]
19. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
[TBL] [Abstract][Full Text] [Related]
20. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
